DaShenLin Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 4/6
DaShenLin Pharmaceutical Group has a total shareholder equity of CN¥8.4B and total debt of CN¥3.0B, which brings its debt-to-equity ratio to 35.8%. Its total assets and total liabilities are CN¥25.5B and CN¥17.1B respectively. DaShenLin Pharmaceutical Group's EBIT is CN¥1.5B making its interest coverage ratio 9.4. It has cash and short-term investments of CN¥5.1B.
Key information
35.8%
Debt to equity ratio
CN¥3.00b
Debt
| Interest coverage ratio | 9.4x |
| Cash | CN¥5.06b |
| Equity | CN¥8.37b |
| Total liabilities | CN¥17.12b |
| Total assets | CN¥25.49b |
Recent financial health updates
Recent updates
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)
Sep 30
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Sep 03DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital
Aug 20Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%
Jun 17Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?
Jun 09Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?
May 21Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings
May 06Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital
Apr 09Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E
Mar 17Financial Position Analysis
Short Term Liabilities: 603233's short term assets (CN¥11.5B) do not cover its short term liabilities (CN¥12.3B).
Long Term Liabilities: 603233's short term assets (CN¥11.5B) exceed its long term liabilities (CN¥4.8B).
Debt to Equity History and Analysis
Debt Level: 603233 has more cash than its total debt.
Reducing Debt: 603233's debt to equity ratio has increased from 35.7% to 35.8% over the past 5 years.
Debt Coverage: 603233's debt is well covered by operating cash flow (115.6%).
Interest Coverage: 603233's interest payments on its debt are well covered by EBIT (9.4x coverage).